GleamWall
中文EN

IVVD Invivyd, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1832038 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.3%
TTM net income YoY-117.7%
TTM EPS YoY15.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-224.4%
Net margin-214.8%
FCF margin-221.0%
EBITDA margin—

Returns

ROE-107.0%
ROA-80.7%
ROIC (approx.)-668.6%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets18.2%
Debt / equity0.00x
Current ratio5.51x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue3.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$53.43M$25.38M
R&D expense$38.31M$137.25M
SG&A expense$66.93M$63.39M
Operating income-$55.56M-$176.88M
Income tax$0$0
Net income-$52.49M-$169.93M
EPS (basic)-0.30-1.43
EPS (diluted)-0.30-1.43
Weighted avg. shares (diluted)172.21M118.56M
Balance sheet
Cash & equivalents$226.69M$69.35M
Receivables$13.92M$10.91M
Inventory—$25.91M
Current assets$247.47M$100.68M
PP&E, net$1.36M$1.51M
Total assets$276.88M$129.51M
Current liabilities$34.16M$61.98M
Total liabilities$35.34M$61.98M
Shareholders' equity$241.54M$67.54M
Shares outstanding281.99M119.84M
Cash flow statement
Operating cash flow-$58.13M-$170.49M
Capital expenditure$155,000$140,000
Free cash flow-$58.29M-$170.63M
Investing cash flow-$155,000-$140,000
Financing cash flow$215.63M$39.33M
Stock-based compensation$11.64M$19.79M
Share buybacks—$0

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.